These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 36469250)

  • 1. Preclinical and Clinical Pharmacokinetics and Bioavailability in Healthy Volunteers of a Novel Formulation of the Selective P2X3 Receptor Antagonist Eliapixant.
    Francke K; Chattopadhyay N; Klein S; Rottmann A; Krickau D; van de Wetering J; Friedrich C
    Eur J Drug Metab Pharmacokinet; 2023 Jan; 48(1):75-87. PubMed ID: 36469250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics.
    Klein S; Gashaw I; Baumann S; Chang X; Hummel T; Thuß U; Friedrich C
    Br J Clin Pharmacol; 2022 Oct; 88(10):4552-4564. PubMed ID: 35437837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P2X3 Receptor Antagonist Eliapixant in Phase I Clinical Trials: Safety and Inter-ethnic Comparison of Pharmacokinetics in Healthy Chinese and Japanese Participants.
    Li X; Haranaka M; Li H; Liu P; Chen H; Klein S; Reif S; Francke K; Friedrich C; Okumura K
    Clin Pharmacokinet; 2024 Jun; 63(6):901-915. PubMed ID: 38907175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability and Pharmacokinetics of TRPV1 Antagonist Mavatrep (JNJ-39439335) Tablet and Capsule Formulations in Healthy Men: Two Open-Label, Crossover, Single-Dose Phase 1 Studies.
    Manitpisitkul P; Shalayda K; Russell L; Sanga P; Williams Y; Solanki B; Caruso J; Moyer JA
    Clin Pharmacol Drug Dev; 2018 Sep; 7(7):699-711. PubMed ID: 29125700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
    Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
    Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study.
    Friedrich C; Francke K; Gashaw I; Scheerans C; Klein S; Fels L; Smith JA; Hummel T; Morice A
    Clin Pharmacokinet; 2022 Aug; 61(8):1143-1156. PubMed ID: 35624408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
    Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
    Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers.
    Liu Y; Jia J; Liu G; Li S; Lu C; Liu Y; Yu C
    Clin Ther; 2009 Apr; 31(4):777-83. PubMed ID: 19446150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Integrated Population Pharmacokinetic Analysis for Posaconazole Oral Suspension, Delayed-Release Tablet, and Intravenous Infusion in Healthy Volunteers.
    Chen L; Krekels EHJ; Heijnen AR; Knibbe CAJ; Brüggemann RJ
    Drugs; 2023 Jan; 83(1):75-86. PubMed ID: 36607589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Tablet Formulation, Food, or Gastric pH on the Bioavailability of Asundexian.
    Kanefendt F; Brase C; Unger S; Kubitza D
    Clin Pharmacol Drug Dev; 2023 Feb; 12(2):219-230. PubMed ID: 36507617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic comparison of sustained- and immediate-release oral formulations of cilostazol in healthy Korean subjects: a randomized, open-label, 3-part, sequential, 2-period, crossover, single-dose, food-effect, and multiple-dose study.
    Lee D; Lim LA; Jang SB; Lee YJ; Chung JY; Choi JR; Kim K; Park JW; Yoon H; Lee J; Park MS; Park K
    Clin Ther; 2011 Dec; 33(12):2038-53. PubMed ID: 22129569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
    Kinzler ER; Pantaleon C; Iverson M; Aigner S
    Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and bioequivalence evaluation of two losartan potassium 50-mg tablets: A single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers.
    Jia JY; Zhang MQ; Liu YM; Liu Y; Liu GY; Li SJ; Lu C; Weng LP; Qi YL; Yu C
    Clin Ther; 2010 Jul; 32(7):1387-95. PubMed ID: 20678685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability.
    Li H; Wei Y; Zhang S; Xu L; Jiang J; Qiu Y; Mangin E; Zhao XM; Xie S
    Clin Drug Investig; 2019 Nov; 39(11):1109-1116. PubMed ID: 31432392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics.
    Bramer SL; Forbes WP
    Clin Pharmacokinet; 1999; 37 Suppl 2():13-23. PubMed ID: 10702883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
    Jenner P; Könen-Bergmann M; Schepers C; Haertter S
    Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of Morphine Sulfate Orodispersible Tablets and Bioequivalence with Immediate-Release Oral Morphine Sulfate Formulations in Healthy Adult Subjects Under Fasting Conditions: Single-Dose Comparative Bioavailability Studies.
    Atrux-Tallau N; Naimi Z; Jaudinot EO
    Clin Drug Investig; 2022 Dec; 42(12):1101-1112. PubMed ID: 36331670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast.
    Schug BS; Brendel E; Chantraine E; Wolf D; Martin W; Schall R; Blume HH
    Br J Clin Pharmacol; 2002 Jun; 53(6):582-8. PubMed ID: 12047482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized Comparative Bioavailability of a Novel Three-Dimensional Printed Fast-Melt Formulation of Levetiracetam Following the Administration of a Single 1000-mg Dose to Healthy Human Volunteers Under Fasting and Fed Conditions.
    Boudriau S; Hanzel C; Massicotte J; Sayegh L; Wang J; Lefebvre M
    Drugs R D; 2016 Jun; 16(2):229-38. PubMed ID: 27028750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.